DNA methylation changes in epithelial ovarian cancer histotypes.

[1]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[2]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[3]  R. Elston,et al.  Hereditary nonpolyposis colorectal cancer (lynch syndromes I and II). II. Biomarker studies , 1985, Cancer.

[4]  T. Smyrk,et al.  Hereditary nonpolyposis colorectal cancer--Lynch syndromes I and II. , 1988, Gastroenterology clinics of North America.

[5]  H. Lynch,et al.  Hereditary ovarian cancer. Pedigree studies, Part II. , 1991, Cancer genetics and cytogenetics.

[6]  H. Leonhardt,et al.  A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei , 1992, Cell.

[7]  B. Trask,et al.  Isolation and characterization of the cDNA encoding human DNA methyltransferase. , 1992, Nucleic acids research.

[8]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[9]  J. Mascarello,et al.  Characterization and Development of UCI 107, a Primary Human Ovarian Carcinoma Cell Line , 1995 .

[10]  J. Mascarello,et al.  Characterization and development of UCI 107, a primary human ovarian carcinoma cell line. , 1996, Gynecologic oncology.

[11]  W. Misdorp,et al.  [DNA ploidy]. , 1995, Tijdschrift voor diergeneeskunde.

[12]  L. Benítez-Bribiesca,et al.  [Hereditary nonpolyposis colorectal cancer. Lynch syndrome]. , 1995, Revista de gastroenterologia de Mexico.

[13]  R. Brown,et al.  Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. , 1996, Cancer research.

[14]  A. V. D. Van Der Zee,et al.  hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.

[15]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[16]  M. Ehrlich,et al.  Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. , 1999, Mutation research.

[17]  G. Aquilina,et al.  Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells , 2000, Oncogene.

[18]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[19]  Mitsuaki Suzuki,et al.  Clinical characteristics of clear cell carcinoma of the ovary , 2000, Cancer.

[20]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[21]  R. L. Baldwin,et al.  BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. , 2000, Cancer research.

[22]  Robert Brown,et al.  Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. , 2001, The American journal of pathology.

[23]  M. Stroun,et al.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[24]  N. B. Atkin.  Microsatellite instability , 2001, Cytogenetic and Genome Research.

[25]  S. Narod.  Tubal ligation and risk of ovarian cancer , 2001, The Lancet.

[26]  G. Pfeifer,et al.  Control of microtubule stability by the RASSF1A tumor suppressor , 2003, Oncogene.

[27]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[28]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[29]  Robert Brown,et al.  The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.

[30]  Paul Cairns,et al.  Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients , 2004, Cancer Research.

[31]  Peter W. Laird,et al.  DNA Hypomethylation and Ovarian Cancer Biology , 2004, Cancer Research.

[32]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[33]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[34]  Jacqueline A. Hall,et al.  CpG island methylation of DNA damage response genes in advanced ovarian cancer. , 2005, Cancer research.

[35]  Wenjun Cheng,et al.  Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract , 2005, Nature Medicine.

[36]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.

[37]  Gordon B Mills,et al.  Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon , 2005, Clinical Cancer Research.

[38]  F. Gilliland,et al.  Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk , 2005, Clinical Cancer Research.

[39]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[40]  M. Maio,et al.  Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients , 2005 .

[41]  D. Brutlag,et al.  A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Katsaros,et al.  Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential , 2006, Cancer.

[43]  Hui-Juan Yang,et al.  Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data , 2006, BMC Cancer.

[44]  M. Ehrlich,et al.  Cancer-linked DNA hypomethylation and its relationship to hypermethylation. , 2006, Current topics in microbiology and immunology.

[45]  Sandya Liyanarachchi,et al.  Prognostic DNA Methylation Biomarkers in Ovarian Cancer , 2006, Clinical Cancer Research.

[46]  Hui Xiao,et al.  Insights into the mechanism of microtubule stabilization by Taxol , 2006, Proceedings of the National Academy of Sciences.

[47]  A. Oza,et al.  Optimal chemotherapy treatment for women with recurrent ovarian cancer , 2007, Current oncology.

[48]  H. Hollema,et al.  Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group , 2007, Clinical Cancer Research.

[49]  J. Chien,et al.  Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance , 2007, Oncogene.

[50]  Chein-Hui Hung,et al.  Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma , 2007, Cancer.

[51]  George S Watts,et al.  DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage , 2008, BMC Medical Genomics.

[52]  Yoh Watanabe,et al.  A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. , 2007, Anticancer research.

[53]  Rochelle L. Garcia,et al.  Alternate molecular genetic pathways in ovarian carcinomas of common histological types. , 2007, Human pathology.

[54]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[55]  Susan J Clark,et al.  DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. , 2008, Gynecologic oncology.

[56]  N. Kiviat,et al.  DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. , 2008, Gynecologic oncology.

[57]  Rochelle L. Garcia,et al.  Molecular Cancer Methylation and Protein Expression of Dna Repair Genes: Association with Chemotherapy Exposure and Survival in Sporadic Ovarian and Peritoneal Carcinomas , 2022 .

[58]  L. Dubeau,et al.  The cell of origin of ovarian epithelial tumours. , 2008, The Lancet. Oncology.

[59]  A. Whittemore,et al.  Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis , 2008, British Journal of Cancer.

[60]  Meng Li,et al.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer , 2009, BMC Medical Genomics.

[61]  Martin Widschwendter,et al.  HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer , 2008, International journal of cancer.

[62]  D. Matei,et al.  Minireview: epigenetic changes in ovarian cancer. , 2009, Endocrinology.

[63]  A. Teschendorff,et al.  An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer , 2009, PloS one.

[64]  A. Whittemore,et al.  A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 , 2009, Nature Genetics.

[65]  L. Ma,et al.  Clinicopathological implications of inactivation of RASSF1A in serous epithelial ovarian cancers. , 2009, European journal of gynaecological oncology.

[66]  M. Ehrlich.  DNA hypomethylation in cancer cells. , 2009, Epigenomics.

[67]  F. Patel,et al.  Utility of Gene Promoter Methylation in Prediction of Response to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) , 2009, Cancer investigation.

[68]  I. Shih,et al.  Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems , 2009, Advances in anatomic pathology.

[69]  A. Reuss,et al.  The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas , 2010, The Journal of pathology.

[70]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[71]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[72]  H. Su,et al.  Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway , 2010, International journal of cancer.

[73]  D. Suh,et al.  High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array. , 2010, Oncology reports.

[74]  陈亮.  Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis , 2010 .

[75]  Daniel E. Deatherage,et al.  Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer , 2010, Laboratory Investigation.

[76]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[77]  L. Shulman.  Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. , 2010, Obstetrics and gynecology clinics of North America.

[78]  X. Zhong,et al.  Epigenetics of ovarian cancer: from the lab to the clinic. , 2010, Gynecologic oncology.

[79]  P. Pharoah,et al.  The inherited genetics of ovarian and endometrial cancer. , 2010, Current opinion in genetics & development.

[80]  S. Murphy,et al.  Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes , 2010, Oncogene.

[81]  D. Suh,et al.  High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array , 2010 .

[82]  Jing Wang,et al.  Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.

[83]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[84]  H. Lai,et al.  Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma , 2010, European journal of clinical investigation.

[85]  Matthias Evert,et al.  Oncogenic and tumor suppressive roles of polo‐like kinases in human hepatocellular carcinoma , 2010, Hepatology.

[86]  Daniel E. Deatherage,et al.  Abstract 3072: Promoter hypermethylation of FBXO32, a novel TGF-β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer , 2010 .

[87]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[88]  L. Cope,et al.  Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. , 2010, American journal of obstetrics and gynecology.

[89]  Luigi Ferrucci,et al.  Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain , 2010, PLoS genetics.

[90]  A. Mutirangura,et al.  HERV-K Hypomethylation in Ovarian Clear Cell Carcinoma Is Associated With a Poor Prognosis and Platinum Resistance , 2010, International Journal of Gynecologic Cancer.

[91]  Thomas Lengauer,et al.  Genomic Distribution and Inter-Sample Variation of Non-CpG Methylation across Human Cell Types , 2011, PLoS genetics.

[92]  Z. Barekati,et al.  Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing a Blood-Based Test in Breast Cancer , 2011, PloS one.

[93]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[94]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[95]  Xingjian Cao,et al.  A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection. , 2011, Clinical laboratory.

[96]  I. Meinhold-Heerlein,et al.  Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles , 2011, Oncology.

[97]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  K. Hess,et al.  Association of BRCA 1 and BRCA 2 Mutations With Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients With Ovarian Cancer , 2011 .

[99]  I. McNeish,et al.  Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. , 2011, Cancer research.

[100]  N. Wentzensen,et al.  Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. , 2011, International journal of cancer.

[101]  M. Esteller,et al.  Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome , 2011, Epigenetics.

[102]  Yong-mei Zhu,et al.  Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.

[103]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[104]  D. Spandidos,et al.  'Genetic profiling' and ovarian cancer therapy (review). , 2011, Molecular medicine reports.

[105]  Fang Fang,et al.  Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis , 2011, Science Translational Medicine.

[106]  M. Ehrlich,et al.  DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. , 2011, Gynecologic oncology.

[107]  A. Sood,et al.  Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. , 2011, Gynecologic oncology.

[108]  Y. Kanai,et al.  Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas , 2012, Carcinogenesis.

[109]  H. Donninger,et al.  RASSF1A and the Taxol Response in Ovarian Cancer , 2012, Molecular biology international.

[110]  Chi-Jung Huang,et al.  Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma , 2012, Molecular Cancer.

[111]  B. Karlan,et al.  Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  A. Thompson,et al.  Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. , 2012 .

[113]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  J. Thigpen.  Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .

[115]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[116]  Xingsheng Yang,et al.  TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer , 2012, Journal of experimental & clinical cancer research : CR.

[117]  L. Elnitski,et al.  Differential Analysis of Ovarian and Endometrial Cancers Identifies a Methylator Phenotype , 2012, PloS one.

[118]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[119]  K. Pantel,et al.  Circulating tumor cells and circulating tumor DNA. , 2012, Annual review of medicine.

[120]  Ben Lehner,et al.  Human genes with CpG island promoters have a distinct transcription-associated chromatin organization , 2012, Genome Biology.

[121]  John Quackenbush,et al.  Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome , 2012, Clinical Cancer Research.

[122]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[123]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[124]  X. Xu,et al.  Frequent SLIT2 Promoter Methylation in the Serum of Patients with Ovarian Cancer , 2012, The Journal of international medical research.

[125]  Nita Ahuja,et al.  The CpG island methylator phenotype: what's in a name? , 2013, Cancer research.

[126]  A. Mes-Masson,et al.  Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. , 2013, Gynecologic oncology.

[127]  R. Brown,et al.  Association of somatic DNAmethylation variability with progression-free survival and toxicity in ovarian cancer patients , 2013 .

[128]  Hao Wang,et al.  SULF2 Methylation Is Associated with In Vitro Cisplatin Sensitivity and Clinical Efficacy for Gastric Cancer Patients Treated with a Modified FOLFOX Regimen , 2013, PloS one.

[129]  Sebastian M. Armasu,et al.  Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer , 2013, Nature Communications.

[130]  Wei Lu,et al.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.

[131]  Sebastian M. Armasu,et al.  Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel. , 2013, Human molecular genetics.

[132]  Constanze Zeller,et al.  The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles. , 2013, The American journal of pathology.

[133]  A. Whittemore,et al.  Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies , 2013, Cancer Causes & Control.

[134]  G. Hu,et al.  A multiplex methylation-specific PCR assay for the detection of early-stage ovarian cancer using cell-free serum DNA. , 2013, Gynecologic oncology.

[135]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[136]  Brooke L. Fridley,et al.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer , 2013, Nature Genetics.

[137]  Shuang-Di Li,et al.  Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression , 2013, The journal of obstetrics and gynaecology research.

[138]  A. Ashworth,et al.  Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor , 2013, The Journal of pathology.

[139]  A. Whittemore,et al.  Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 , 2013, Nature Communications.

[140]  R. Lucito,et al.  Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis. , 2013, Gynecologic oncology.

[141]  R. Brown,et al.  Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[142]  P. Peltomäki,et al.  Distinct molecular profiles in Lynch syndrome‐associated and sporadic ovarian carcinomas , 2013, International journal of cancer.

[143]  William Wheeler,et al.  Characterizing the genetic basis of methylome diversity in histologically normal human lung tissue , 2014, Nature Communications.

[144]  Li Lin,et al.  Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[145]  Gangning Liang,et al.  Gene body methylation can alter gene expression and is a therapeutic target in cancer. , 2014, Cancer cell.

[146]  P. Peltomäki,et al.  Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation , 2014, Epigenetics.

[147]  Jian-Bing Fan,et al.  Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status , 2014, Scientific Reports.

[148]  K. Nephew,et al.  Hypermethylation of the TGF-β target, ABCA1 is associated with poor prognosis in ovarian cancer patients , 2015, Clinical Epigenetics.

[149]  K. Odunsi,et al.  LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. , 2014, Gynecologic oncology.

[150]  S. Murphy,et al.  Epigenetic and genetic dispositions of ovarian carcinomas , 2014, Oncoscience.

[151]  Jian Wen,et al.  miR‐145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6 , 2014, International journal of cancer.

[152]  Brigitte Rack,et al.  DNA methylation markers for early detection of women's cancer: promise and challenges. , 2014, Epigenomics.

[153]  Hongbing Shen,et al.  Erratum: Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women (Nature Communications (2014) 5 ((4682)) , 2014 .

[154]  Holger Heyn,et al.  Linkage of DNA methylation quantitative trait loci to human cancer risk. , 2014, Cell reports.

[155]  A. Berchuck,et al.  Epigenetic determinants of ovarian clear cell carcinoma biology , 2014, International journal of cancer.

[156]  Rahul Bhagat,et al.  Microsatellite instability, promoter methylation and protein expression of the DNA mismatch repair genes in epithelial ovarian cancer. , 2014, Genomics.

[157]  R. Zeillinger,et al.  BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). , 2014, European journal of cancer.

[158]  D. Spandidos,et al.  DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review) , 2014, Molecular medicine reports.

[159]  C. Ling,et al.  Genome-Wide Associations between Genetic and Epigenetic Variation Influence mRNA Expression and Insulin Secretion in Human Pancreatic Islets , 2014, PLoS genetics.

[160]  James D. Brenton,et al.  Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes , 2014, PloS one.

[161]  Yuan-Yuan Su,et al.  Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis. , 2014, Genetic testing and molecular biomarkers.

[162]  Matthew D. Schultz,et al.  Human Body Epigenome Maps Reveal Noncanonical DNA Methylation Variation , 2015, Nature.

[163]  Yurii B. Shvetsov,et al.  Genome-wide significant risk associations for mucinous ovarian carcinoma , 2015, Nature Genetics.

[164]  B. Fridley,et al.  Abstract 4246: Comparison of pathology versus IHC-based ovarian carcinoma histology assignment using gene expression, DNA methylation, and clinical outcome data , 2015 .

[165]  S. You,et al.  Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. , 2015, American journal of translational research.

[166]  Yurii B. Shvetsov,et al.  Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk , 2015, PloS one.

[167]  S. Murphy,et al.  Hepatocyte nuclear factor‐1β (HNF‐1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma , 2015, Molecular carcinogenesis.

[168]  Kconfab Investigators,et al.  Identification of six new susceptibility loci for invasive epithelial ovarian cancer , 2015 .

[169]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[170]  G. Samimi,et al.  Methylation of cell-free circulating DNA in the diagnosis of cancer , 2015, Front. Mol. Biosci..

[171]  G. Heinze,et al.  Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer. , 2015, Cancer letters.

[172]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.